Features

Features

Alternative commercialisation models offer lifeline to future of gene therapies

Cell and gene therapies (CGTs) have captured significant interest in the pharma industry, with the modality being explored in multiple…

Annabel Kartal Allen

Features

Magazine: Biopharma’s 2025 M&A boom

Features

Pharma positions itself for 2026 amid an evolving US landscape

Features

States consider payment limits to curb prescription drug prices with PDABs

Features

High-value oncology deals drive China’s drug licensing boom

Features

Biopharma’s 2025 M&A boom: Dealmaking surges as patent pressures intensify

Features

In a Honduran city, biotechs create gene therapy cocktails to fight aging

Features

Podcast: What key trends are people talking about in pharma?

Features

Veeva Summit Europe: future-proofed AI set to bolster commercial pharma operations

Annabel Kartal Allen

Features

New protein manufacturing technologies likely to play key role in “five to ten years”

Annabel Kartal Allen

Features

Raising the bar: can higher drug spending in the UK deliver for pharma and patients?

Features

Estonia’s digital health DNA: Trust, data, and biotech in focus

Catherine Longworth

Features

Psychedelics potential set to extend beyond mental health

Annabel Kartal Allen

Features

Magazine: Cleanroom chronicles

Features

From Nobel to next-gen: Sweden’s quiet life sciences ascent

Features

New US biotech hubs show potential amid onshoring requests

Annabel Kartal Allen

Features

Pharma R&D set to endure despite rising MFN costs

Features

NewCo licensing models are tipping deals in favour of China’s biotechs

Frankie Fattorini

Features

The Baltics: a region punching above its weight on the global life sciences stage

Features

Magazine: China’s CGT edge

Features

What does the EU Data Act mean for businesses?

Features

As US funding falters, mRNA cancer vaccine pioneers face new hurdles

Features

Podcast: key trials and trends from ESC Congress 2025

Features

Cell and gene therapies on correction course but not sinking

Features

Animal testing alternatives to dominate, but not overnight

Annabel Kartal Allen

Features

Magazine: Big biopharma take on the ADC challenge

Features

Accelerating diagnosis and drug development with better managed datasets

Features

A new way forward in ovarian cancer: why synthetic iMSCs could change the paradigm

Features

Podcast: US tariff news and Q2 earnings influence pharma trends

Robert Barrie and Manasi Vaidya

Features

Europe’s cannabis pharmaceuticals market matures amid cautious investment

Catherine Longworth

Features

Targeting energy expenditure: the next wave of obesity drugs

Frankie Fattorini

Features

Synthetic rescue: Insmed explores a new frontier in genetic therapeutics

Catherine Longworth

Features

Can rare disease research in the US thrive under the new administration?

Features

EU’s Pharma Package falls short of Europe’s goal of global competitiveness

Frankie Fattorini

Features

Why can’t the US figure out weight loss drug prices?

Features

How will RFK Jr’s American dream for vaccines play out?

Features

EHDS regulation will depend on strong patient confidence

Features

From discovery to delivery: making therapies reach patients faster

Sign up to the newsletter: In Brief

I would also like to subscribe to:

Pharma Technology Focus : Pharmaceutical Technology Focus (monthly)

Thematic Take (monthly)

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close